Preferential involvement of a phospholipase A2-dependent pathway in CD69-mediated platelet activation.
CD69 is a signal transducing disulfide-linked homodimer functionally expressed on platelets, CD3bright thymocytes, and activated lymphocytes. In an attempt to investigate early molecular events in CD69-mediated cell activation we studied the relative contribution of phospholipase A2 (PLA2) and phosphatidylinositol-specific phospholipase C-dependent pathways during platelet activation induced by CD69 stimulation. Thromboxane A2 (TXA2) synthetase inhibitor and TXA2R inhibitor R68070 were able to inhibit platelet aggregation induced by CD69 stimulation, indicating that TXA2 was the main mediator of the response. CD69-induced arachidonic acid release and TXA2 production were essentially PLA2 dependent because they could be blocked by the PLA2 inhibitor quinacrine. Inositol 1,3,4-trisphosphate generation was clearly detectable after CD69 cross-linking, but it was completely abrogated by quinacrine and R68070 and therefore secondary to TXA2 release and TXA2R engagement. Finally, direct measurement of enzymatic activity in vitro using radiolabeled phospholipid vesicles showed that CD69 cross-linking resulted in PLA2-dependent arachidonic acid and lysophosphatidylcholine generation from phosphatidylcholine, which was sensitive to quinacrine but not to R68070. By contrast, CD69-induced 1,2-diacylglycerol release from phosphatidylinositol 4,5-bisphosphate was blocked by both inhibitors. These results indicate a preferential involvement of PLA2 in CD69-dependent signal transduction in platelets and provide evidence for the unique role of PLA2-mediated activation pathways in transmembrane receptor signaling.
Testi
R
R
Department of Experimental Medicine, University of Rome La Sapienza, Italy.
Pulcinelli
F M
FM
Cifone
M G
MG
Botti
D
D
Del Grosso
E
E
Riondino
S
S
Frati
L
L
Gazzaniga
P P
PP
Santoni
A
A
D015703:Antigens, CD / Q000502:physiology*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000502:physiology*; D016718:Arachidonic Acid / Q000378:metabolism; D004075:Diglycerides / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D007295:Inositol Phosphates / Q000096:biosynthesis; D037181:Lectins, C-Type; D010421:Pentanoic Acids / Q000494:pharmacology; D043265:Phosphatidylinositol Diacylglycerol-Lyase; D054801:Phosphoinositide Phospholipase C; D010741:Phospholipases A / Q000502:physiology*; D054467:Phospholipases A2; D010727:Phosphoric Diester Hydrolases / Q000502:physiology; D015539:Platelet Activation / Q000187:drug effects / Q000276:immunology*; D011725:Pyridines / Q000494:pharmacology; D011796:Quinacrine / Q000494:pharmacology; D011982:Receptors, Prostaglandin / Q000502:physiology; D017482:Receptors, Thromboxane; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D000099192:CD69 Antigens
D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D016718:Arachidonic Acid; D004075:Diglycerides; D007295:Inositol Phosphates; D037181:Lectins, C-Type; D010421:Pentanoic Acids; D043265:Phosphatidylinositol Diacylglycerol-Lyase; D054801:Phosphoinositide Phospholipase C; D010741:Phospholipases A; D054467:Phospholipases A2; D010727:Phosphoric Diester Hydrolases; D011725:Pyridines; D011796:Quinacrine; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D013930:Thromboxane-A Synthase; D000099192:CD69 Antigens; C011439:1,2-diacylglycerol; C058097:inositol 1,3,4-trisphosphate; C060219:ridogrel